OxThera Phase 3 Study With Oxabact® in Primary Hyperoxaluria is Now Open for Recruitment
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, announced that the Phase 3 study with Oxabact® in Primary Hyperoxaluria (PH) is now fully open for recruitment. All clinics participating in the study are approved by Competent authorities […]
